At a glance
ClinicalIndex Comparison RecordPhase 3Recruiting· 400 target
Drug / intervention
HB0017 Q4W +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06477237Phase 3RecruitingUpdate OverdueUpdated 24mo ago · Completion was 22mo agoEnrollment Stalled
Update Overdue
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of HB0017 Injection in Patients With Moderate to Severe Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating HB0017 Q4W, HB0017 Q8W, and 1 other intervention for Psoriasis. Currently recruiting, targeting 400 participants across 44 sites.
Signals
Enrollment appears stalled
Detailed Summary
This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study which is designed to determine the efficacy, safety, immunogenicity and pharmacokinetics, and pharmacodynamics of HB0017 Injection in the treatment of moderate to severe plaque psoriasis in adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesChina
Collaborators--
Timeline
Phase 3RecruitingOverdue
20252026
Enrollment StartMar 2024
First PostedJun 2024
Primary CompletionAug 2024
Study CompletionDec 2025
TodayJul 2026
First PostedJun 27, 2024
Enrollment StartMar 1, 2024
Primary CompletionAug 1, 2024
Study CompletionDec 1, 2025
TodayJul 1, 2026
Enrollment to primary: 5 monthsPosted 2.0 years ago
Interventions
HB0017 Q4Wbiological
HB0017 at W0,1,2,4,8+HB0017Q4W
HB0017 Q8Wbiological
HB0017 at W0,1,2,4,8+HB0017Q8W
placebobiological
placebo at W0,1,2,4,8+HB0017Q4W